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S Glossary of Terms
Definitions from Article 2 of the 
Convention on Biological Diversity:
•	 “Biological diversity” means the vari-
ability among living organisms from all 
sources including, inter alia, terrestrial, 
marine and other aquatic ecosystems 
and the ecological complexes of which 
they are part; this includes diversity 
within species, between species and of 
ecosystems. 
•	 “Biological resources” includes genetic 
resources, organisms or parts thereof, 
populations, or any other biotic com-
ponent of ecosystems with actual or 
potential use or value for humanity. 
•	 “Biotechnology” means any techno-
logical application that uses biological 
systems, living organisms, or derivatives 
thereof, to make or modify products or 
processes for specific use. 
•	 “Country of origin of genetic resources” 
means the country which possesses 
those genetic resources in in-situ condi-
tions. 
•	 “Country providing genetic resources” 
means the country supplying genetic 
resources collected from in-situ sources, 
including populations of both wild and 
domesticated species, or taken from 
ex-situ sources, which may or may not 
have originated in that country. 
•	 “Domesticated or cultivated species” 
means species in which the evolutionary 
process has been influenced by humans 
to meet their needs. 
•	 “Ecosystem” means a dynamic complex 
of plant, animal and micro-organism 
communities and their non-living envi-
ronment interacting as a functional unit. 
•	 “Ex-situ conservation” means the con-
servation of components of biological 
diversity outside their natural habitats. 
•	 “Genetic material” means any material 
of plant, animal, microbial or other origin 
containing functional units of heredity. 
•	 “Genetic resources” means genetic 
material of actual or potential value (tan-
gible and intangible). 
•	 “Habitat” means the place or type of 
site where an organism or population 
naturally occurs. 
•	 “In-situ conditions” means conditions 
where genetic resources exist within 
ecosystems and natural habitats, and, in 
the case of domesticated or cultivated 
species, in the surroundings where they 
have developed their distinctive proper-
ties. 
•	 “In-situ conservation” means the con-
servation of ecosystems and natural 
habitats and the maintenance and 
recovery of viable populations of spe-
cies in their natural surroundings and, in 
the case of domesticated or cultivated 
species, in the surroundings where they 
have developed their distinctive proper-
ties. 
7•	 “Protected area” means a geographi-
cally defined area which is designated 
or regulated and managed to achieve 
specific conservation objectives. 
•	 “Sustainable use” means the use of 
components of biological diversity in 
a way and at a rate that does not lead 
to the long-term decline of biological 
diversity, thereby maintaining its poten-
tial to meet the needs and aspirations of 
present and future generations.
Definitions from Article 2 of the 
Nagoya Protocol:
•	 “Utilization of genetic resources” means 
to conduct research and development 
on the genetic and/or biochemical com-
position of genetic resources, including 
through the application of biotechnology 
as defined in Article 2 of the Convention; 
•	 “Derivative” means a naturally occurring 
biochemical compound resulting from 
the genetic expression or metabolism 
of biological or genetic resources, even 
if it does not contain functional units of 
heredity. 
NP   Nagoya Protocol on Access and   
 Benefit Sharing
CBD   Convention on Biological Diversity 
DNA   Deoxyribonucleic acid
PIC   Prior Informed Consent 
ABS   Access and Benefit Sharing 
DOO   Disclosure of Origin
COP   Conference of the Parties 
UN   United Nations 
LMOs   Living Modified Organisms 
TBD    To Be Determined 
EU    European Union
NGO    Non-Governmental Organization
GR   Genetic Resource 
TK    Traditional Knowledge 
MATs  Mutually Agreed Terms
IP   Intellectual Property 
Acronyms
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This report assesses how implementation of 
the Nagoya Protocol on Access and Benefit 
Sharing (NP) to the Convention on Biological 
Diversity (CBD) may affect U.S. researchers 
working in the area of synthetic biology.  It 
also analyzes selected provisions in CBD-
related national legislation predating the NP 
that may be relevant for such researchers. 
The report concludes that numerous ques-
tions remain unanswered, both with respect 
to the time period covered by CBD/NP and 
with respect to what sorts of genetic material 
are covered.  Despite this uncertainty, and 
despite the fact that the U.S. is not a party 
Executive Summary 
to the CBD/NP, U.S. researchers would be 
well-advised to: 
1. inquire into the origin of tangible genetic 
material that they use and, where appli-
cable, to
2. ensure that such material was taken in 
compliance with the domestic law of a 
provider country  
With respect to digital genetic information, 
determining origin is likely to be more difficult. 
Even so, provider countries may assert that 
such information falls within the scope of the 
CBD/NP.
9Synthetic biology aims to take genetic engi-
neering to a new level. Whether this new level 
will ultimately be revolutionary or evolutionary 
remains to be seen.  Revolutionary advances 
might allow full-scale application of engineer-
ing principles like standardization, decoupling 
of information from manufacture, and ab-
straction, with the result that well-character-
ized DNA parts could readily be assembled in 
many different ways to generate predictable 
outputs.1  On the other hand, if current levels 
of unpredictability in biology continue to 
perplex researchers,2 synthetic biology may 
be better understood as a suite of evolution-
ary advances in DNA synthesis and system 
modeling that allow more rapid design of new 
microbial systems.3  
Regardless of how the technology develops 
in the future, synthetic biology research into 
improving DNA sequences (including not 
only full sequences that code for proteins but 
also sequences that have other functions) 
has already utilized significant quantities 
of tangible genetic material.4  Additionally, 
the emergence of firms that can synthesize 
relatively long DNA sequences accurately 
has highlighted the central role of intangible 
genetic information.5  
For purposes of compliance with the CBD/
NP, one key question is whether particular 
genetic material and information represents 
“genetic resources.” As shown in the glos-
sary,6 the CBD and NP define “genetic re-
sources” to mean “genetic material of actual 
or potential value.”  Genetic material, in turn, 
means any material that contains “functional 
units of heredity.”  
Neither the CBD nor the NP defines “func-
tional units of heredity.”7  Thus it is unclear 
whether all categories of DNA sequences 
are covered.  In addition, important ques-
tions regarding the reach of the CBD/NP into 
intangible genetic information or so-called 
derivative products remain unanswered. We 
address these issues in the Implementation 
Issues Section. Before addressing these and 
other specific issues of implementation, how-
ever, we provide relevant historical and policy 
background on the CBD/NP, particularly with 
respect to the U.S. role.
Synthetic Biology and Genetic Resources
10
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The CBD is designed to facilitate the conser-
vation of biological diversity, the sustainable 
use of its components, and the fair and eq-
uitable sharing of the benefits generated by 
the use of genetic resources.8 It establishes 
that genetic resources should be viewed not 
as the common heritage of mankind, freely 
available to all, but instead as the property 
of sovereigns who make access to them 
available under principles of prior informed 
consent (PIC) and access and benefit sharing 
(ABS).9  
The CBD is an environmental treaty in the 
sense that it was driven by a desire to stem 
the uncontrolled depletion of flora and fauna 
diversity, largely in the global south. But the 
agreement was also designed to address 
concerns relating to “biopiracy.”  Biopiracy 
has been defined as “[t]he patenting of 
plants, genes, and other biological prod-
ucts that are indigenous to a foreign country 
without compensating the keepers of those 
resources and the holders of knowledge 
appropriated during ethnobiological research 
processes.”10   Compensation, in turn, would 
presumably provide an incentive for appropri-
ate biodiversity conservation going forward. 
The CBD has 193 members and went into 
effect in 1993.  Its key principles include the 
following:
•	 States have sovereign control over 
biological resources within their borders 
and shall ensure conservation of same 
(Art. 3);
•	 States shall endeavor to create con-
ditions to facilitate access on mutu-
ally agreed terms and subject to prior 
informed consent (Art. 15(2)); 
•	 There should be fair and equitable 
sharing of benefits of use of genetic 
resources with the providing party (Art. 
15(7)); and
•	 Any wider application of traditional 
knowledge (TK) shall be with the ap-
proval and involvement of TK holders 
(Art. 8(j)).11
Although then-President Bill Clinton signed 
the CBD in 1993 on behalf of the United 
States, the treaty was never ratified by the 
U.S. Senate.  Consequently, the United 
States is not a party to either the CBD or 
the NP.  The U.S. is also opposed to CBD-
implementing legislation in many countries 
which, for example, links ABS/PIC obligations 
with patent protection through a disclosure 
of origin requirement for genetic resources 
used in creating an invention. (See Box: U.S. 
Opposition to linking ABS/PIC) For example, 
as discussed later, the 2009 amendments to 
the Chinese Patent Act included provisions 
requiring patent applicants to disclose the 
country of origin of relevant genetic resources 
used in creating an invention and denying 
patent protection to inventions created with 
genetic resources obtained in violation of 
Chinese law. 
In addition, for many years, a number of 
countries rich in genetic resources (so-called 
“provider countries”) have been pressing in 
several multilateral fora for ABS/PIC treaty 
provisions and a new Disclosure of Origin 
(DOO) patentability requirement. Such efforts 
have generally been consistent with, and 
designed to give effect to, the CBD.  Many of 
these countries also have created, or are in 
the process of creating, biodiversity legisla-
tion, first to comply with the CBD and more 
Background on the Convention on Biological 
Diversity and the Nagoya Protocol
11
recently to implement the NP after it comes 
into force. Most countries do not view treaty 
obligations as self-implementing; rather, they 
must be incorporated into domestic law by 
implementing legislation.12  
Most countries embrace dualism.  However, 
some dualist countries do allow treaties to 
have direct effect in national law on a case-
by-case basis.13 Implementing legislation 
often is also necessary because treaty terms 
may lack specificity regarding how obliga-
tions are to be met, leaving such details to 
individual countries to decide.
The Conference of the Parties (COP) is the 
governing body of the CBD and takes deci-
sions at periodic meetings to advance imple-
mentation of the Convention.  Its decisions 
include the promulgation of the Cartagena 
Protocol on Biosafety,14 which went into ef-
fect in 2003, adoption of the Bonn Guidelines 
on Access to Genetic Resources and the 
Fair and Equitable Sharing of the Benefits 
Arising from their Utilization in 200215 (See 
Appendix for full text of Bonn Guidelines) 
and, at its Tenth meeting in 2010 Nagoya, 
Japan, the Nagoya Protocol on Access and 
Benefit Sharing to the Convention on Biologi-
cal Diversity (“NP”). The Bonn Guidelines and 
the NP were necessary because, while the 
CBD obligated Parties to facilitate access 
to their genetic resources, and to fairly and 
equitably share benefits arising from the 
utilization of genetic resources with provider 
countries, it provided almost no detail on how 
ABS should be accomplished in practice.16  
Consequently, provider countries had wide 
latitude in developing legislation to implement 
the CBD, creating a miasma of legal uncer-
tainty for users faced with often burdensome 
rules for ABS/PIC that varied significantly 
by country.  Over the eighteen years that 
elapsed between adoption of the CBD and 
adoption of the NP, the Parties studied and 
debated ways to move forward on this issue. 
Although the Bonn Guidelines were a helpful 
step in providing further specificity on ABS 
and PIC, they are not binding on Parties.  
The NP, as a binding agreement, is a logical 
step in the evolution of a detailed framework 
to reduce uncertainty and provide increased 
uniformity for both users and providers of 
genetic resources and associated TK.17  
That said, whether the NP ultimately fulfills its 
goal of bringing greater certainty and unifor-
mity will depend on how it is implemented 
and ultimately comes into effect.  Although 
the NP was adopted in 2010, it will not for-
mally come into effect until ninety days after 
the fiftieth instrument of ratification is depos-
ited with the CBD. 18  Ninety-two countries 
signed the agreement, and twenty-six have 
ratified it at the time of this writing. Interest-
ingly, some countries, such as China, that 
are parties to the CBD, did not sign the NP 
before the deadline for signatures passed. 
Nevertheless, such countries can still ac-
cede to the Protocol at a later date, and even 
countries not parties to the CBD can accede 
to the Protocol as long as they also become 
a contracting party to the CBD at the same 
time. In addition to ratifying the NP, member 
countries must enact legislation to imple-
ment the Agreement.  It is expected that the 
Agreement will come into effect in 2014 at 
the earliest.
The NP has two main foci: access and user 
compliance.  The access provisions give 
Parties significant leeway to decide whether 
they wish to regulate ABS and require PIC for 
their genetic resources.  If a country decides 
to regulate ABS/PIC, it then must implement 
the rather detailed NP international access 
12
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standards, which build on and incorporate 
aspects of the Bonn Guidelines to create a 
framework for ABS/PIC.  Regarding user-
compliance, the NP requires all Parties to 
ensure that only legally acquired genetic 
resources and associated TK are utilized in 
their jurisdictions, to monitor user compliance 
via checkpoints (e.g., when receiving public 
funding), and allow for ABS contract disputes 
to be resolved in court.  However, the NP 
allows a fair amount of Party discretion in 
choosing particular user-compliance imple-
menting measures.19   
The NP includes the following key provisions:
•	 It is applicable to genetic resources cov-
ered by CBD Article 15, to the benefits 
arising from the utilization of such re-
sources, as well as to traditional knowl-
edge associated with such resources 
and benefits arising from utilization of 
such knowledge (Art. 3).
•	 It incorporates the definitions provided 
in the CBD and additionally defines 
“derivatives” and “utilization of genetic 
resources” (Art. 2).
•	 It leaves to the discretion of the par-
ties whether to regulate access to 
their genetic resources and associated 
traditional knowledge, and require prior 
informed consent and benefit sharing 
(ABS/PIC).  However, any parties choos-
ing to require PIC must implement, 
through binding legislation, the detailed 
access standards specified in the Proto-
col (Art. 6).
•	 It specifies that, consistent with CBD 
Art. 15, benefits arising from genetic 
resource utilization shall be shared in a 
fair and equitable way with the Providing 
Party and shall be upon mutually agreed 
terms (MAT) (Art. 5).
•	 It encourages countries to explore the 
need for and modalities of a global mul-
tilateral benefit sharing mechanism/fund 
to facilitate benefit sharing (Art. 10).
•	 It requires countries to designate national 
focal points for access and benefit shar-
ing, so as to make information available 
to users, providers and the COP, on the 
procedures for obtaining PIC and comply-
ing with ABS requirements (Art. 13). 
•	 It requires countries to designate one or 
more checkpoints to collect information 
from users of genetic resources when 
users claim, for example, an intellec-
tual property right relating to a prod-
uct developed from genetic resource 
utilization. It also provides for certain 
government-issued permits to serve as 
internationally recognized certificates 
of compliance;20 evidence that covered 
genetic resources have been accessed 
in accordance with PIC/ABS on mutually 
agreed terms (Art. 17).
•	 Several of its Articles also deal with ABS 
and PIC obligations when traditional 
knowledge is used (e.g., Arts. 7 & 12).
13
Article 4 also explains how the NP relates 
to other existing and future treaties, noting 
that the NP does not affect Party rights and 
obligations in relation to other existing agree-
ments, except when exercising those provi-
sions would seriously damage or threaten bi-
ological diversity.  It also states that although 
it is the instrument for implementing the ABS 
provisions of the CBD, it does not apply 
to Parties of other specialized international 
agreements with ABS provisions that are 
consistent with the objectives of the CBD and 
NP in respect of the specific genetic resource 
covered by the specialized instrument.  Thus, 
for example, the sharing of genetic resources 
for food and agriculture is excluded from the 
NP, as such are covered by the International 
Treaty on Plant Genetic Resources for Food 
and Agriculture (ITPGRFA).21
14
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A U.S. Group response to a 2010 AIPPI question-
naire on the “Requirement of Indicating the Source 
and/or Country of Origin of Genetic Resources 
and Traditional Knowledge in Patent Applications” 
sums up the Position of the United States on this 
issue:
While the United States has been monitoring the 
proposals that have been made in a variety of fora 
to allow or mandate that national patent legislation 
require the declaration of the source of genetic 
resources and traditional knowledge in patent 
applications as well as demands for sharing of 
benefits from the commercialization of products 
utilizing them, the US government, with the strong 
support of US companies, has taken the position 
that these initiatives are unwise and unnecessary.* 
A separate document explains reasons for the U.S. 
position:
We further note that there appears to be a pre-
sumption by the proponents, without empirical 
evidence, that an invention related to a genetic 
resource is automatically based upon illegal access 
or misappropriation absent concrete evidence to 
the contrary.  However. . . many genetic resources 
are indeed commercially sold, legally obtained, 
and independently researched and developed into 
inventions.  Even within publicly accessible inter-
national and national gene banks, there are many 
resources where the country of origin is unknown.  
Even assuming arguendo, that new disclosure 
requirements could achieve the purported goals, 
new patent disclosure requirements would be 
unworkable given the absence of knowledge of 
country of origin for numerous publicly available 
resources.  However. . . such new disclosure re-
quirements create legal uncertainty and increased 
burdens on the patent system, as well as negative 
effects on benefit sharing, but will not prevent the 
purported acts of misappropriation or bad patents.  
These objectives must be accomplished through 
national ABS systems upon access to the material 
initially.  These examples lead to the conclusion 
that new patent disclosure requirements will not 
achieve the desired objectives and that incorpora-
tion of such requirements in the patent system 
would stifle innovation and undermine the patent 
system.**
There are no pending bills or discussions that 
would suggest that legislation will be introduced 
on these issues within the United States. It should 
also be noted that the United States is not a party 
to the Convention on Biological Diversity [CBD], 
and no pending legislation exists that would alter 
that status.
Box 1
*International Association for the Protection of Intellectual Property (AIPPI), Questionnaire February 2010: Special Com-
mittees Q 94—WTO/TRIPS and Q166—Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore 
on the Requirement of Indicating the Source and/or Country of Origin of Genetic Resources and Traditional Knowledge in 
Patent Applications: Communication from the US Group (Apr. 7, 2010).  
**Council for Trade-Related Aspects of Intellectual Property Rights, Communication by the United States, Article 27.3(b), 
Relationship Between the TRIPS Agreement and the CBD, and the Protection of Traditional Knowledge and Folklore, IP/
C/W/469, para. 37 (Mar. 13, 2006).  See also Jonathan Carr, Agreements That Divide:  TRIPS vs. CBD and Proposals for 
Mandatory Disclosure of Source and Origin of Genetic Resources in Patent Applications, 18 J. Transnat’l L. & Policy 131, 
144 (2008) (discussing U.S. opposition to proposed TRIPS disclosure of origin amendments). Nevertheless, regulations 
are apparently in place for U.S. government agencies to comply with CBD and Protocol requirements when engaging in 
commercial and noncommercial scientific research. See Geoff Burton, Implementation of the Nagoya Protocol in JUSCANZ 
Countries: The Unlikely Lot, p. 311, in The 2010 Nagoya Protocol on Access and Benefit-Sharing in Perspective: Implications 
for International Law and Implementation Challenges, Elisa Morgera, Matthias Buck & Elsa Tsioumani, eds. (Martinus Nijhoff 
Pub. 2012). While such provisions do not govern private sector and non-U.S.-government public sector research, certain 
entities, such as the Biotechnology Industry Organization (BIO), have published best practice guidelines for members to 
follow to comply with the CBD.  See BIO, Guidelines for BIO Members Engaging in Bioprospecting, http://www.bio.org/
sites/default/files/Guidelines%20for%20BIO%20Members%20Engaging%20in%20Bioprospecting_0.pdf.
U.S. opposition to linking ABS/PIC obligations with patent protection through a disclosure 
of origin requirement for genetic resources used in creating an invention
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In this section, we address specific CBD/NP 
implementation issues relevant for synthetic 
biology researchers.  These issues, which are 
somewhat interrelated, include the impact 
of legislation predating the NP, the temporal 
scope of CBD/NP obligations, and the scope 
of materials and information covered.
By way of preface, we note that the NP does 
not explicitly address synthetic biology at 
any point, nor does it appear that the topic 
received much discussion during negotia-
tions on the NP. A 2008 CBD ad hoc expert 
group report did note that the term “deriva-
tive,” while not the subject of any common 
understanding, denotes  “a continuum of 
very general to very specific concepts.” This 
broad language is not, however, found in the 
NP itself. The NP’s definition of a derivative is 
discussed further below.
(c) Gene segments produced or isolated 
by human manipulation of genetic  
material.
(d) Synthetic gene segments produced by 
human manipulation (one segment be-
ing a derivative of all the various genetic 
materials used in its construction).
(e) Information or knowledge derived from 
genetic materials in general or a specific 
gene sequence in particular. 
(f) Synthetic analogue chemicals or gene 
segments inspired by a particular 
naturally occurring metabolite or gene 
segment. . . .
(j) Something derived from biological and 
genetic resources such as varieties, 
strains or breeds, blood, proteins, oils, 
resins, gums, genes, seeds, spores, 
pollen, urine, bark, wood, leaf matter 
and the like as well as the products 
derived from, patterned on, or incorpo-
rating manipulated compounds and/or 
genes[.]22  
In Decision XI/11, adopted during the Elev-
enth COP meeting 9-18 October 2012 in 
Hyderabad, India, the CBD COP requested 
input from parties and other stakehold-
ers on new and emerging issues relating to 
the components, organisms and products 
resulting from synthetic biology techniques 
that may have impacts on the conserva-
tion and sustainable use of biological diver-
sity and associated social, economic and 
cultural considerations.23   This request is 
further evidence of the lack of any meaning-
ful discussion of, or consensus regarding, 
the NP’s applicability to synthetic biology 
inputs and products during negotiation of the 
agreement.  Draft documents submitted to 
the COP in response to the request identify 
a wide range of issues and uncertainties re-
garding the NP and synthetic biology that will 
need to be resolved over time if there is to be 
a harmonized approach to this topic.24  In the 
meantime, individual countries seem free to 
interpret their existing domestic biodiversity 
legislation, or insert provisions in their draft 
NP implementing legislation, to cover syn-
thetic biology inputs and products.  To date, 
we have been unable to identify any country’s 
legislation, draft or existing, that explicitly 
addresses synthetic biology as such.25 That 
said, as discussed below, language in certain 
legislation may be deemed to encompass 
activities conducted by synthetic biologists. 
Implementation Issues
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Legislation Predating the NP
At least fifty-seven countries and seven 
regions have some type of patchwork 
biodiversity and/or ABS/PIC legislation for 
implementing the CBD that predates the 
NP.26  Such legislation, often contained in 
biodiversity and/or patent laws, takes a wide 
variety of forms.  
China: For example, China has over fifty 
biodiversity-related laws, at least some of 
which regulate access and benefit sharing in 
relation to genetic resources.27 The country 
also incorporated genetic resource provisions 
in the most recent (third) amendment to the 
Chinese Patent Act which went into effect 
in 2009.28 Article 5 of the Third Amendment 
denies patentability to any invention created 
using genetic resources obtained in violation 
of Chinese law. 29 The new Article 5 states:  
“Patents shall not be granted for 
inventions or creations that violate 
the law, run counter to social ethics 
or jeopardize the public interest.  If 
genetic resources are obtained or 
used in violation of laws or adminis-
trative regulations and an invention 
or creation is completed on the basis 
of such genetic resources, the pat-
ent shall not be granted therefor.”
However, once a patent has been granted, the 
fact that it is later determined that the inventor 
violated a Chinese genetic resource law would 
not be a basis for invalidating that patent.
The implementing guidelines for the revised 
Chinese Patent Act define genetic resources 
to include genetic material extracted from 
the human body, animals, plants, or micro-
organisms which contain functional units of 
heredity. 30  In addition to Article 5, the revised 
Act contains another provision related to ge-
netic resource acquisition, Article 26, which 
requires applicants to disclose the country of 
origin of relevant genetic resources in addi-
tion to the direct supplier.31  Article 26, states 
in part:
“For an invention or creation com-
pleted based on genetic resources, 
the applicant shall give an account 
in the patent application documents 
of the direct origin and ultimate 
origin of the genetic resources.  If 
the applicant is unable to give an 
account of the ultimate origin, it/he/
she shall give the reason therefor.”
Failure to supply the required information is 
a basis for rejecting claims in an application, 
but apparently not for invalidating an already 
issued patent.32  
Brazil: The laws of some other countries go 
further.  For example, a Brazilian law regu-
lating access to components of Brazilian 
genetic heritage contains a variety of penal-
ties for violation of genetic resource laws in 
creating patentable inventions.  Such penal-
ties include: payment to the Federal Govern-
ment of at least twenty percent of the gross 
income or royalties from commercializing or 
licensing the resulting product (benefit shar-
ing); suspension or cancellation of the result-
ing patent, and much more.  Additionally, the 
origin of genetic material used in creating an 
invention must be disclosed in the patent 
application.33  
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India: India’s Biodiversity Act has even stiffer 
penalties for applying for patent protection on 
an invention created with genetic resources 
obtained without complying with the ABS/
PIC provisions of the Act: fines and imprison-
ment, although the law does allow violators 
to obtain the necessary permissions after the 
fact. However, whether provider countries 
actually enforce these laws consistently or 
even arbitrarily, is unknown. (See Box, India’s 
Biodiversity Act)34  
Section 2 of the Act defines “biological 
resources” as including plants, animals 
and micro-organisms or parts thereof, their 
genetic material and by-products.  Unlike 
the Chinese regime, India’s legislation does 
not encompass human genetic material; 
likewise, the NP, incorporating CBD Deci-
sion X/1, does not currently include human 
genetic resources although that may be 
further considered by the COP in the future.35 
This wide diversity of approaches to ABS/
PIC was part of the impetus for negotiation 
and adoption of the NP, especially as pre-NP 
provider country legislation tends to focus on 
illegal access and use of genetic resources 
obtained from that country as opposed to 
the NP’s more global focus on ensuring that 
genetic resources and associated traditional 
knowledge are acquired under the relevant 
ABS/PIC legislation of any country from 
which they are originally obtained.  However, 
as discussed below, the NP, while bring-
ing uniformity to some aspects of ABS/PIC, 
leaves several areas for continued member 
country divergence.
Others: As of this writing, only six countries 
and the EU have submitted, to the CBD COP, 
implementing legislation for the NP and, in 
most cases, that legislation is still in draft 
form (and in a non-English language, namely 
French, Danish, or Spanish).  For example, 
draft implementing legislation in Denmark 
provides for fines and up to two years impris-
onment for utilizing genetic resources ac-
quired in violation of a given country’s access 
regulations, so long as the activity in question 
was willful or grossly negligent.36 Thus, enti-
ties that use genetic resources obtained from 
a provider country in a manner that violates 
the PIC/ABS legislation of the provider will 
risk the imposition of penalties (civil and/or 
criminal) against them not only in the provider 
country but perhaps also in other countries 
that penalize extraterritorial genetic resource 
access violations. In addition, it is important 
to remember that many provider countries 
already have PIC/ABS legislation in effect 
that complies with many of the requirements 
of the NP despite predating it, and may thus 
require only minimal adjustments (particularly 
to harmonize with the NP’s access require-
ments) to be fully compliant.  
Temporal Scope (Retroactivity)
As noted, the NP will come into effect ninety 
days after fifty countries ratify the agreement.  
But that fact does not resolve the question of 
whether the agreement will apply to genetic 
material acquired prior to the NP’s effective 
date under conditions that would not sat-
isfy its requirements. Indeed, an important 
question not clearly addressed by the NP 
and currently the subject of intense debate is 
whether user obligations are triggered only at 
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the time of initial resource access/removal or 
extend to the time of utilization. This issue is 
also referred to as temporal scope, with two 
primary temporal triggers:  CBD ratification 
(1993) and NP ratification (TBD).37  Significant 
genetic resources will have been accessed 
in provider countries prior to the entry into 
force of the NP (and others even before the 
CBD).  But new utilization of many of those 
resources, currently held in gene or seed 
banks, botanical gardens, or private collec-
tions outside the provider country, will take 
place only after the effective date of the NP. 
Legislation implementing the NP clearly will 
make users of genetic material physically 
accessed for the first time after the NP takes 
effect subject to its obligations. However, it is 
unclear if governments will impose NP obliga-
tions on entities making new uses of genetic 
resources obtained from provider countries 
prior to the entry into force of the NP.  
Article 28 of the Vienna Convention on the 
Law of Treaties, an agreement on treaty 
interpretation, provides that a treaty does 
not have retroactive effect unless the par-
ties agree otherwise.38  Because the parties 
to the NP were unable to agree on temporal 
scope during the multiyear negotiations, the 
Agreement is silent on the topic. This silence 
does not, however, settle the question, as the 
parties may also disagree on what represents 
retroactivity.  Provider countries may view a 
utilization trigger as not prohibiting retroactiv-
ity but, rather, giving effect to the terms and 
spirit of the NP.39  This is particularly likely 
to be the case because more than twenty 
such countries have, since 1993, enacted 
PIC/ABS legislation with obligations tied to 
access and/or utilization, to effectuate the 
CBD.  These countries include the Andean 
Community (Bolivia, Columbia, Ecuador, and 
Peru), Denmark, Ethiopia, India, Brazil, Ke-
nya, Norway, Panama, the Philippines, South 
Africa, and Vietnam.40  
Definitions of what constitutes true access 
are also contested.  As two observers of the 
NP negotiations explain: 
One fairly common opinion among 
user countries was that a genetic 
resource is accessed at the point 
in time when the biological sample 
is crossing a border; by contrast, 
provider countries often opined 
that access occurs when biological 
material is used for the purpose of 
taking advantage of its genetic ma-
terial, independent of when and un-
der which conditions the biological 
material actually crosses a border. . 
. . To establish a functional system 
for implementing the NP, countries 
will need to agree on when “access” 
happens.41
Because the NP is silent on “when access 
happens,” user countries may choose to 
implement the agreement in a manner that 
imposes obligations only on genetic resourc-
es that cross a border after the NP comes 
into force. That is the apparent approach of 
the draft implementing legislation for the EU, 
which states
19
Article 2: Scope
This Regulation applies to genetic 
resources over which states exercise 
sovereign rights and to traditional 
knowledge associated with genetic 
resources that are accessed after the 
entry into force of the Nagoya Protocol 
for the Union. It also applies to the 
benefits arising from the use of such 
genetic resources and to traditional 
knowledge associated with genetic 
resources. . . .42
The EU draft legislation is expected to 
comprehensively implement only the user-
compliance obligations of the NP by means 
of a regulation, which will ensure the highest 
level of harmonization because it will apply in 
all member countries without implementing 
legislation.  However, the legislation leaves 
member countries free to craft their own NP 
implementing legislation to address ABS and 
PIC if they so desire.  Consequently, there is 
expected to be no direct conflict between EU 
and member state NP implementing legisla-
tion.43
Similarly, implementing legislation proposed 
by Switzerland states that NP obligations 
apply only to “access to genetic resources 
or associated traditional knowledge that has 
occurred after the said provisions came into 
force.”44 Japan has also indicated that its 
implementing legislation will not have what it 
considers retroactive effect.45  
The EU/Swiss approach has been criticized 
by NGOs and a special European Commis-
sion rapporteur, all of which argue that to 
achieve the goals of the NP and provide legal 
certainty for users and providers, new uses 
of genetic resources accessed prior to the 
NP must be subject to its requirements.46  
Under such a construction, genetic resources 
acquired decades ago from a member coun-
try without complying with ABS/PIC, and 
maintained in repositories in another country 
during the intervening time period, would be 
subject to the NP’s ABS/PIC requirements at 
any future time they were used in research 
and/or to create new products. 
Similarly, the ABS Management Tool: Best 
Practice Standard and Handbook for Imple-
menting Genetic Resource Access and 
Benefit Sharing Activities recommends that 
users of genetic resources comply with the 
domestic legislation in the providing country, 
which would include legislation that makes 
utilization the trigger for NP compliance.47 
Parties pushing for a utilization trigger for Pro-
tocol obligations point to several concerns, 
as explained in comments on the EU draft 
legislation:
First, a significant share of GRs and 
associated TK used in the EU will 
not be covered by the Regulations, 
thereby undermining the spirit of the 
Nagoya Protocol. Second, individual 
users of GRs and TK will not be 
able to receive what they always 
wanted: legal certainty. In many 
cases, the utilization of GR and 
TK will be legal under EU law, but 
illegal under the law of the provider 
country. Although the user has 
received an approval from European 
au thorities, he or she could be pros-
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ecuted in a provider country upon 
setting foot in that country. Nobody 
is interested in such scenario.48
Consequently, the issue of the temporal 
scope of the Nagoya Protocol obligations 
remains very uncertain and is likely to stay 
that way for the foreseeable future. 
The Breadth of CBD/NP Coverage 
In addition to temporal scope, issues regard-
ing the scope of materials covered by the 
CBD/NP remain unresolved.  As noted in Part 
II, an initial open question revolves around 
what is meant by the term “functional unit 
of heredity.”  In the time period (1989-1992) 
when the CBD was negotiated, the scientific 
focus was on full gene sequences that coded 
for proteins.  Thus, at the time, the term may 
have referred primarily to full sequences that 
coded for proteins.49  By contrast, the DNA 
“parts” that synthetic biology researchers 
develop may represent only parts of cod-
ing regions or may emerge from non-coding 
regions that regulate gene expression.  It is 
unclear whether a partial coding sequence or 
a DNA sequence that regulates gene expres-
sion constitutes a functional unit of heredity.  
In general, as biological science, including 
synthetic biology, moves away from a focus 
on individual full gene sequences towards 
a focus on parts of genes as well as the full 
genome and proteome, it is unclear how the 
notion of a “functional unit of heredity” will map 
onto the new science.  Provider countries are 
likely to argue that the term encompasses all 
DNA sequences, while user countries may 
argue for a narrower interpretation. 
  Provider countries may also point to a 2008 
Report by a Working Group of Legal and 
Technical Experts that specifically discusses 
the utilization of genetic resources as encom-
passing “[g]enetic modification of a micro-
organism for a specific purpose” as well 
as “use of genetic material as a ‘factory’ to 
produce organic compounds.”  As currently 
practiced, synthetic biology does indeed use 
genetically engineered micro-organisms (e.g., 
yeast) to produce chemical compounds such 
as artemisinin, isoprene, and vanillin.50
  With improvement in DNA synthesis tech-
nology, synthetic biology increasingly relies 
on transfers of digital information rather than 
transfer of physical material. The use of the 
term “genetic material” in the CBD/NP sug-
gests that intangibles do not fall within the 
scope of the CBD/NP.  On the other hand, 
some have argued for a “broad and dynamic” 
understanding of the concept of genetic 
resources that would encompass digital infor-
mation.51  In this regard, it is notable that the 
Andean Community Commission’s Common 
Regime on Access to Genetic Resources, 
adopted in 1996, includes a reference to 
genetic information.  It defines genetic 
resources as “all biological material that con-
tains genetic information of value or of real 
or potential use.”52 In addition, the Brazilian 
Provisional Act of 2001 defines genetic heri-
tage broadly as “information of genetic origin, 
contained in samples of all or part of a plant, 
fungal, microbial or animal species . . .” 53
Note that although sequence information 
could conceivably be a genetic resource, 
it is unlikely to have been derived from the 
provider community and thus seems unlikely 
to constitute traditional knowledge.
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If the CBD/NP is deemed to cover sequence 
information, and access is deemed to occur 
when that information “crosses a border,” 
(see discussion in Section IV.B), the issue 
of what constitutes a border becomes an 
interesting one.  User countries, which have 
pushed for a “crossing the border” definition 
of access, might try to argue that the move-
ment of digital information out of the country 
should not be considered the equivalent of 
crossing a physical border.   
Further questions arise in the context of 
so-called derivatives.  As noted, synthetic 
biology currently uses genetically modified 
organisms to produce chemicals, such as 
artemisinin, isoprene, and vanillin, which 
have natural analogs.54 Article 2 of the NP 
defines a derivative as “a naturally occurring 
biochemical compound resulting from the 
genetic expression or metabolism of biologi-
cal or genetic resources, even if it does not 
contain functional units of heredity.”  Thus 
various products of synthetic biology would 
appear to fall within Article 2.  However, 
derivatives are not explicitly included in the 
scope of Article 3, and thus commentators 
differ on whether the NP’s obligations should 
be deemed to extend to them or should be 
confined to genetic resources.55  
 Like the controversy over temporal scope, 
the controversy over the NP’s breadth, 
particularly with respect to derivative prod-
ucts, is likely to pit provider countries against 
user countries. Provider countries are likely 
to view any use of genetic resources, even 
uses much farther down the supply chain in 
which the original genetic resource has been 
very substantially modified, or comprises only 
a very small part of the whole, as triggering 
ABS obligations.  Conversely, countries that 
limit obligations to the time of accessing the 
genetic resource may, to some degree, ef-
fectively limit the NP’s applicability to deriva-
tive products, as later uses of the resources 
simply will not be known at the time the 
genetic resource is accessed and the ABS 
agreement is drawn up.  Making the NP 
applicable to derivative products could have 
the negative effect of dis-incentivizing the use 
of genetic resources in research and com-
mercialization endeavors.  By the same token, 
denying the applicability of the NP to deriva-
tive products could result in provider countries 
making access requirements more onerous 
which could dis-incentivize research into previ-
ously un-accessed genetic resources. 
One NP bright spot for researchers is the 
Article 8 provision requiring Parties to create 
“simplified measures on access for non-com-
mercial research purposes.”  This provision 
was included in recognition of the need for 
streamlined access to genetic resources for 
initiatives such as the International Barcode 
of Life (iBOL) project on DNA barcoding 
species identification efforts.56  Article 8 does 
suggest, however, that a change in the nature 
of such research from non-commercial to 
commercial would need to be addressed.  
Relevance for Researchers
Article 15 of the NP requires each party to 
take appropriate measures to ensure that ge-
netic resources utilized within its jurisdiction 
have been accessed in compliance with the 
PIC/ABS domestic legislation of the provid-
ing country and that mutually agreed terms 
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(MATs) have been established.   Because the 
United States is not a party to the NP, it is 
not likely to impose any such requirement for 
the use of genetic resources.  Nevertheless, 
U.S. researchers entering provider countries, 
seeking to obtain new genetic resources from 
such countries, or even seeking to obtain 
intellectual property rights in any country 
(including a user country) that has PIC/ABS 
legislation over inventions developed with 
genetic resources accessed and/or used in 
violation of a provider country’s domestic leg-
islation, may be subject to the range of legal 
action specified in such legislation, including, 
in some cases, imprisonment.   Consequent-
ly, researchers in the United States would be 
well-advised to:
•	 Inquire as to the origin of genetic re-
sources used in research and seek to 
comply with the domestic legislation of 
the identified provider country regard-
ing PIC/ABS/ MAT (the ABS Handbook 
provides a “best practices” approach).
•	 Continue to monitor the development 
of both NP implementing legislation in 
member countries and the COP explo-
ration of emerging issues under COP 
Decisions VIII/10 and XI/11, including 
synthetic biology and its relation to the 
NP. Both in the submissions to the COP 
and in the choice of agenda items for 
future DOP meetings.57 
•	 Provide input and advice to legislators 
in user and provider countries who are 
drafting NP implementing legislation to 
ensure concerns regarding synthetic 
biology coverage, and temporal scope 
are considered and addressed.  
23
India’s Biodiversity Act
The Biodiversity Act provides in part:
“6.         (1) No person shall apply for any intellectual property right by whatever name called in or outside 
India for any invention based on any research or information on a biological resource obtained from India 
without obtaining the previous approval of the National Biodiversity Authority before making such applica-
tion: 
Provided that if a person applies for a patent, permission of the National Biodiversity Authority may be 
obtained after the acceptance of the patent but before the sealing of the patent by the patent authority 
concerned.
  (2) The National Biodiversity Authority may, while granting the approval under this section, impose 
benefit sharing fee or royalty or both or impose conditions including the sharing of financial benefits arising 
out of the commercial utilisation of such rights.
. . . .
Penalties.
55.       (1) Whoever contravenes or attempts to contravene or abets the contravention of the provisions of 
section 3, section 4, or section 6 shall be punishable with imprisonment for a term which may extend to 
five years, or with fine which may extend to ten lakh rupees and where the damage caused exceeds ten 
lakhs such fine may be commensurate with the damage caused, or with both . . .
 57.       (1) Where an offence or contravention under this Act has been committed by a company, every 
person who at the time the offence or contravention was committed was in charge of, and was responsible 
to the company for the conduct of the business of the company, as well as the company, shall be deemed 
to be guilty of the offence or contravention and shall be liable to be proceeded against and punished ac-
cordingly:
. . . .  
Provided that nothing contained in this sub-section shall render any such person liable to any punishment 
provided in this Act, if he proves that the offence or contravention was committed without his knowledge or 
that he had exercised all due diligence to prevent the commission of such offence or contravention.”
Box 2
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Significant genetic resources will have been 
accessed in provider countries prior to the 
entry into force of the NP (and others even 
before the CBD).  But new utilization of many 
of those resources, currently held in gene or 
seed banks, botanical gardens, or private 
collections outside the provider country, will 
take place only after the effective date of the 
NP.  Consequently, until countries agree on 
the temporal scope of NP obligations (i.e., 
whether they apply only to materials ac-
cessed in a member country after ratification 
of the NP or also to genetic materials ac-
cessed before, but utilized after, ratification 
of the NP), there will continue to be a lack of 
uniformity and legal uncertainty for research-
ers using genetic resources in their work. 
Moreover, failure to comply with the ABS/PIC 
provisions of any country may affect the abil-
ity of researchers to obtain IP rights, certain 
kinds of funding, or other benefits in jurisdic-
tions such as the EU.
Synthetic biology researchers, who often 
work on DNA sequences that do not code for 
a full protein, or with genetic information only, 
face additional uncertainty.  Neither the CBD 
nor the NP defines “functional units of hered-
ity.”   Thus it is unclear whether all categories 
of DNA sequences are covered.  In addition, 
important questions regarding the reach of 
the CBD/NP into intangible genetic informa-
tion or so-called derivative products remain 
unanswered.
Implementation of the Nagoya Protocol by 
member countries is in its infancy, thus many 
questions regarding how the agreement will 
be implemented cannot currently be an-
swered.  This can be seen as an opportunity 
however, for researchers and other interested 
parties to actively engage the political pro-
cess in particular countries to provide input 
into how the NP should be implemented.
Conclusion
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Bonn Guidelines
A major achievement of COP VI was the 
adoption of the Bonn guidelines on access 
to genetic resources and the fair and equi-
table sharing of the benefits arising from their 
utilization (see Decision VI/24). 
The Guidelines were recognized as a use-
ful first step of an evolutionary process in 
the implementation of relevant provisions of 
the Convention related to access to genetic 
resources and benefit-sharing. They will be 
kept under review by the COP and the need 
for their further refinement will be considered 
on the basis of relevant developments under 
the Convention, including those on issues 
such as traditional knowledge and technol-
ogy transfer. 
The guidelines should assist Parties, Govern-
ments and other stakeholders in developing 
an overall access and benefit-sharing strat-
egy, and in identifying the steps involved in 
the process of obtaining access to genetic 
resources and benefit-sharing. More specifi-
cally, these voluntary guidelines are meant 
to assist Parties, Governments and other 
stakeholders when establishing legislative, 
administrative or policy measures on access 
and benefit-sharing and/or when negotiat-
ing contractual arrangements for access and 
benefit-sharing. 
Parties and relevant organizations have been 
invited to provide financial and technical as-
sistance to support developing countries, in 
particular least developed countries, small 
island developing states, as well as countries 
with economies in transition, in implementing 
the Bonn Guidelines. 
The second meeting of the Ad Hoc Open-
ended Working Group on Access and 
Benefit-sharing, held in Montreal from 1 to 
5 December 2003, considered experience 
gained from the use of the Bonn Guidelines, 
based on information shared by Parties and 
stakeholders. 
The Conference of the Parties at its seventh 
meeting, in Decision VII/19 addressed the 
Bonn Guidelines under section A. The COP 
recognized “that the Guidelines are making 
a useful contribution to the development of 
national regimes and contractual arrange-
ments for access and benefit-sharing and to 
the implementation of the objectives of the 
Convention”. It also recognized that some 
developing countries had encountered con-
straints due to inadequate capacity to fully 
utilize the guidelines in the formulation of their 
national access and benefit-sharing legisla-
tion. Parties, Governments, indigenous and 
local communities and all relevant stakehold-
ers were invited to continue to promote the 
wide implementation of the voluntary Bonn 
Guidelines. They were also encouraged to 
submit further information on relevant experi-
ence and lessons learned, including success-
es and constraints, in the implementation of 
the Guidelines. The Executive Secretary is 
to make this information available through 
appropriate means, including the Clearing 
House Mechanism of the Convention. Other 
issues of relevance to the Bonn Guidelines 
were also addressed by the Conference of 
the Parties in Decision VII/19, such as the 
use of terms, and other approaches, comple-
mentary to the Bonn Guidelines to assist with 
the implementation of the ABS provisions of 
the Convention. 
Appendix
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At its eighth meeting, in decision VIII/4 B, the 
Conference of the Parties noted the progress 
already accomplished and urged Parties 
to continue implementing the Bonn Guide-
lines and to share experiences and lessons 
learned in their implementation as well as 
in the development and implementation of 
national and sub-national measures. Informa-
tion provided to the Secretariat related to the 
implementation of the Bonn Guidelines has 
been compiled in information documents.58 
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The Synthetic Biology Project was established in 
August 2008 at the Woodrow Wilson International 
Center for Scholars. The Project aims to foster 
informed public and policy discourse concerning the 
advancement of synthetic biology—an emerging 
interdisciplinary field that uses advanced science and 
engineering to make or re-design living organisms, 
such as bacteria, so that they can carry out specific 
functions. Synthetic biology involves making new 
genetic code, also known as DNA, which does not 
already exist in nature.
Work of the Synthetic Biology Project is supported by a 
grant from the Alfred P. Sloan Foundation.
For more information about the Project visit: www.
synbioproject.org 
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